Clinical Validation of New Injection Molded Flocked Nasopharyngeal Swabs in Response to the COVID-19 Pandemic
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 40
- 试验地点
- 2
- 主要终点
- Number of Subjects for Which the Prototype Swab and the Control Swab Provide the Same COVID-19 PCR Result
研究概览
简要总结
The SARS-CoV-2 pandemic has resulted in an international shortage of the nasopharyngeal (NP) swabs used to collect sample for virological testing. This shortage has become a crisis as testing capacity is growing, and threatens to become the bottleneck at University of Virginia Health System and in the Commonwealth of Virginia, as it already is in other testing centers. To resolve this crisis, a team in the Clinical Microbiology Laboratories at University of Virginia Medical Center has been working closely with biomedical engineers in the University of Virginia (UVA), School of Engineering and with high volume domestic manufacturers developing injection molded polypropylene flocked nylon NP swab.
This prototype will be tested for non-inferiority relative to existing, already validated NP swabs ("control swab") for purposes of molecular microbiology: i.e. the polymerase chain reaction (PCR) tests used for virological testing for SARS-CoV-2. Specifically, the nasopharynx of patients with Covid-19 and patients under investigation (PUI) for Covid-19, the disease caused by SARS-CoV-2, will be swabbed using a prototype swab and a control swab (the standard of care swab), and test for concordance of SARS-CoV-2. In all cases the swab will be transported in validated FDA cleared viral transport medium (VTM) as per standard operating procedure at University of Virginia Medical Center.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Other
- 盲法
- None
入排标准
- 年龄范围
- 0 Years 至 99 Years(Child, Adult, Older Adult)
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Individuals presenting to the site for clinical care will be evaluated for clinical screening for Covid-19 testing or other respiratory infection testing.
- •Individuals felt identified clinically as needing Covid-19 testing may be approached for study participation.
- •Individuals already under clinical care that have tested positive for Covid-19 will be approached for study participation.
- •Volunteer health care workers who have approached the Principal Investigator
排除标准
- •Known thrombocytopenia of <50,000 platelets/μl (risk of mild bleeding).
- •Individuals presenting with an anatomically altered nasal cavity.
- •Pregnant (self-reported)
- •No other patients will be specifically excluded.
结局指标
主要结局
Number of Subjects for Which the Prototype Swab and the Control Swab Provide the Same COVID-19 PCR Result
时间窗: at time of enrollment
Both the prototype and control nasopharyngeal swabs will be utilized in each subject. The rate of agreement between the swabs will be determined by the number of subjects for which both swabs provide the same COVID-19 PCR result.
次要结局
未报告次要终点
研究者
Amy Mathers, MD
Associate Professor, Department of Medicine, Infectious Disease
University of Virginia
